Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co LLY reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes.
Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses, compared to just 2.4% on placebo.
Related: ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs.
Lilly did not report p-values for the study but instead produced figures as "efficacy estimands," representing the efficacy before discontinuation.
Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of placebo.
In a key secondary endpoint, 55% (10 mg) and 63% (15 mg) of people taking tirzepatide achieved at least 20% body weight reductions compared to 1.3% in the placebo.
Price Action: LLY shares are up 5.12% at $299.69 during the market session on the last check Thursday.